Beneficial Ownership Report · SCHEDULE 13G
Replimune Group, Inc.
REPLNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- REPLIMUNE GROUP INC
- Company CIK
- 0001737953
- Street
- 500 UNICORN PARK DRIVE 3RD FLOOR
- City
- WOBURN
- State / country code
- MA
- Postal code
- 01801
Statement details
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- STATE STREET CORPORATION
- Citizenship / organization
- MA
- Reporting person type
- HC
- Aggregate amount owned
- 4,174,260.00
- Percent of class
- 4.4
- Sole voting power
- 0.00
- Shared voting power
- 4,080,714.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 4,174,260.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
REPLIMUNE GROUP INC
Principal executive office address
500 UNICORN PARK DRIVE 3RD FLOOR, WOBURN, MASSACHUSETTS, 01801
Item 2
Citizenship
MA
Filing person
STATE STREET CORPORATION;
Principal business or residence address
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
4.4
Amount beneficially owned
4174260.00
Sole voting power
0
Shared voting power
4,080,714
Sole dispositive power
0
Shared dispositive power
4,174,260
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
NOT APPLICABLE
Item 7
Not applicable indication
N
Subsidiaries
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);
Item 8
Not applicable indication
N
Group members
NOT APPLICABLE
Item 9
Not applicable indication
N
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- STATE STREET CORPORATION
- Signed
- ALOK MAHESHWARY
- Title
- SENIOR VICE PRESIDENT
- Date
- 11/09/2026
Company context
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.